EyePoint (EYPT) Non-Current Assets (2011 - 2026)
EyePoint (EYPT) posted Non-Current Assets of $38.7 million for Q1 2026, up 9.54% sequentially from $35.3 million in Q4 2025, and up 8.8% YoY from $35.6 million in Q1 2025.
EyePoint (EYPT) Non-Current Assets (2011 - 2026) Analysis & Trends
EyePoint has reported Non-Current Assets for 16 years, with the latest figure at $38.7 million in Q1 2026.
- Quarterly Non-Current Assets rose 8.8% year-over-year to $38.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $145.5 million (up 9.9% YoY) and the FY2025 annual result came in at $35.3 million, up 0.52% from the prior year.
- Non-Current Assets advanced to $38.7 million in Q1 2026 per EYPT's latest filing, from $35.3 million in the prior quarter.
- Over five years, Non-Current Assets peaked at $38.7 million in Q1 2026 and troughed at $7.5 million in Q4 2022.
- A 5-year average of $24.4 million and a median of $28.4 million in 2022 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2022 and 2024: Non-Current Assets plunged 70.55% in 2022, then soared 243.42% in 2024.
- Over 5 years, Non-Current Assets stood at $7.5 million in 2022, then soared by 37.57% to $10.4 million in 2023, then jumped by 238.59% to $35.2 million in 2024, then rose by 0.52% to $35.3 million in 2025, then climbed by 9.54% to $38.7 million in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $38.7 million, $35.3 million, and $35.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | EyePoint | 1.25 Bn | 1.07 Bn | 507,000.00 | 39.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 39.37 Mn |
| Mar 31, 2026 | 38.71 Mn |
| Dec 31, 2025 | 35.34 Mn |
| Sep 30, 2025 | 35.59 Mn |
| Jun 30, 2025 | 35.90 Mn |
| Mar 31, 2025 | 35.58 Mn |
| Dec 31, 2024 | 35.16 Mn |
| Sep 30, 2024 | 32.37 Mn |
| Jun 30, 2024 | 29.32 Mn |
| Mar 31, 2024 | 11.54 Mn |
| Dec 31, 2023 | 10.38 Mn |
| Sep 30, 2023 | 9.88 Mn |
| Jun 30, 2023 | 8.54 Mn |
| Mar 31, 2023 | 8.54 Mn |
| Dec 31, 2022 | 7.55 Mn |
| Sep 30, 2022 | 28.39 Mn |
| Jun 30, 2022 | 27.57 Mn |
| Mar 31, 2022 | 24.93 Mn |
| Dec 31, 2021 | 25.63 Mn |
| Sep 30, 2021 | 26.48 Mn |